Oncology
4 drugs are in development for Acute Myeloid Leukemia.
- Companies
- 4
- Clinical trials
- 150
Prepared research question
Which programs lead the Acute Myeloid Leukemia pipeline—and what evidence could change the picture?
Traceable citations · Unknowns marked
Drug Pipeline by Phase
| Drug | Company |
|---|---|
| BMF-500 | Biomea Fusion, Inc. (BMEA) |
| inkmune | Inmune Bio, Inc. (INMB) |
| sl-172154 | Shattuck Labs, Inc. (STTK) |
About this indication
Acute Myeloid Leukemia context
Also known as: ANLL, Acute Myeloblastic Leukemia, Acute Myeloblastic Leukemias, Acute Myelocytic Leukemia, Acute Myelocytic Leukemias, Acute Myelogenous Leukemias, Acute Myeloid Leukemias, Acute Nonlymphoblastic Leukemia, Acute Nonlymphoblastic Leukemias, Acute Nonlymphocytic Leukemia, Acute Nonlymphocytic Leukemias, Leukemia, Myeloblastic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myelogenous, Acute, Leukemia, Myeloid, Acute, Leukemia, Nonlymphoblastic, Acute, Leukemia, Nonlymphocytic, Acute, Myelogenous Leukemia, Acute
Prevalence
6.0 / 100K
Incidence
4.3 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Acute Myeloid Leukemia?
BioSniper tracks 4 drugs in development for Acute Myeloid Leukemia across 4 companies.
How many clinical trials target Acute Myeloid Leukemia?
There are 150 clinical trials targeting Acute Myeloid Leukemia tracked by BioSniper.
What is the prevalence of Acute Myeloid Leukemia?
The estimated prevalence of Acute Myeloid Leukemia is approximately 6.0 per 100,000 population.